Interview with Allan Marchington, Partner, Apposite Capital LLP
As a partner at Apposite since the company was created in 2006, what was the founding vision of the company and what do you consider have been its major milestones…
Address: Bracken House One Friday Street EC4M 9JA,United Kingdom
Tel: +44 (0)20 7090 6190
Web: http://www.appositecapital.com/
Apposite Capital is an independent investment firm focused exclusively on Healthcare. The firm invests in private companies involved in Healthcare Services and Life Sciences on a primary basis, as well as acquiring and managing direct Healthcare assets in the secondary market.
Apposite has an in-depth sector knowledge covering all aspects of the healthcare industry, with a unique unrivalled reach to Japan. The investment team combines complementary entrepreneurial, private equity and investment banking skills.
Apposite has built a high quality primary portfolio of companies in the US and Europe. The firm invests in seasoned management with a clear vision and is committed to add value to its portfolio companies. Apposite balances its investments across all stages of company development, providing venture, development, growth and small mid market buyout capital. Apposite typically invests as a lead investor and has representation on the Board of Directors.
The firm invests in private companies involved in Healthcare Services and Life Sciences on a primary basis, as well as acquiring and managing direct Healthcare assets in the secondary market.
As a partner at Apposite since the company was created in 2006, what was the founding vision of the company and what do you consider have been its major milestones…
Throughout his long career, John-Arne Rottingen has gathered experience across multiple domains from discovery research to public health and diplomacy that led him to become the founding CEO of the…
A roundup of some of the biggest stories coming out of the UK pharma industry, including AstraZeneca’s bid for cancer specialist Fusion Pharmaceuticals; the shutdown of Sanofi’s R&D site in…
Last year the UK-based pharma industry warned against the country’s waning competitiveness, condemning the government’s statutory scheme designed to control drug prices. UK-headquartered AstraZeneca joined the battle cry, claiming it…
The recent FDA decision to investigate the serious risk of patients developing new cancers after treatment with CAR-T therapies may have created some bad press around cell and gene therapies,…
A roundup of the biggest stories from UK pharma, including the latest agreement between the British government and industry on a renewed drug pricing clawback scheme; GSK’s search for deals…
AstraZeneca has made a bold move by offering its in-house digital clinical trial expertise to clinical research organisations (CROs) and other pharmaceutical companies via the launch of healthtech business Evinova.…
Since its creation over 20 years ago, the National Institute for Health and Care Excellence (NICE), the Health Technology Assessment (HTA) body for England and Wales, has forged a solid…
Could the UK’s re-joining of Horizon Europe, the EU’s EUR 95 billion research funding programme, be the latest sign that the country is ready to win back its global scientific…
The latest news from UK healthcare and life sciences, including the safety review of Novo Nordisk’s GLP-1 receptor agonists; VaxEquity’s grant to scale up RNA vaccine manufacturing; AstraZeneca/Quell Therapeutics cell…
Life sciences have been steadily losing ground in the UK with a significant drop in global R&D investments and a decreasing number of patients enrolled in clinical trials. The British…
Several macro-trends affected the pharmaceutical industry in 2022, impacting its inventory position, writes Matthew Bardell, managing director of specialist inventory consultants nVentic. Bardell highlights findings in a recent report –…
The latest news from UK healthcare and the life sciences, including a record rise in the number of people using private healthcare services due to significant strains on the National…
See our Cookie Privacy Policy Here
